{Reference Type}: Journal Article
{Title}: Dupilumab: Mechanism of action, clinical, and translational science.
{Author}: McCann MR;Kosloski MP;Xu C;Davis JD;Kamal MA;
{Journal}: Clin Transl Sci
{Volume}: 17
{Issue}: 8
{Year}: 2024 Aug
{Factor}: 4.438
{DOI}: 10.1111/cts.13899
{Abstract}: Allergic disease prevalence has increased globally with the subset of type 2 inflammatory diseases playing a substantial role. Type 2 inflammatory diseases may differ in clinical presentation, but they exhibit shared pathophysiology that is targeted by the unique pharmacology of dupilumab. Dupilumab binds to the interleukin (IL)-4 receptor alpha subunit (IL-4Rα) that blocks IL-4 and IL-13 signaling, two key drivers of type 2 inflammation. Herein, we review the mechanism of action and pharmacology of dupilumab, and the clinical evidence that led to the regulatory approvals of dupilumab for the treatment of numerous type 2 inflammatory diseases: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.